Home › NDC Lookup › RxCUI directory › RxCUI 847261

3 ML insulin glulisine, human 100 UNT/ML Pen Injector [Apidra] — RxCUI 847261

Name: 3 ML insulin glulisine, human 100 UNT/ML Pen Injector [Apidra] (RxCUI 847261)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 847261 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI847261

Official name3 ML insulin glulisine, human 100 UNT/ML Pen Injector [Apidra]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known as3 ML Apidra 100 UNT/ML Pen Injector; Apidra 100 UNT/ML in 3 ML Pen Injector; Apidra 100 UNT/ML per 3 ML SoloSTAR Pen

FDA products mapped2

Package NDCs mapped4

Reported Medicaid activity (SDUD)18,473 prescriptions · 33 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Insulin Glulisine (rDNA origin) Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Apidra is designed to be taken close to your meal. You can inject it within 15 minutes before you start eating, or within 20 minutes after you've begun your meal. Because it acts s...
When exactly should I inject Apidra — before or after I eat?
The only insulin you can mix with Apidra in a syringe is NPH insulin. If you do mix them, draw Apidra into the syringe first, then inject immediately — don't let it sit after mixin...
Can I mix Apidra with my long-acting insulin in the same syringe?

📖 Read our full Insulin Glulisine (rDNA origin) Injection guide →

🕸️ Concept Web — How 3 ML insulin glulisine, human 100 UNT/ML Pen Inj... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 3 ML insulin glulisine, human 100 UNT/ML Pen Injector [Apidra] RxCUI 847261 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Insulin glulisine, human 400008 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Apidra 607583 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Insulin glulisine, human Pen Injector 1651313 SCDF
- Insulin glulisine, human Injectable Product 1157464 SCDG
- Insulin glulisine, human Pen Injector [Apidra] 1651315 SBDF
- Apidra Injectable Product 1168563 SBDG
- Pen Injector 1649571 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 3 ML insulin glulisine, human 100 UNT/ML Pen Injector 847259 SCD
- Insulin glulisine, human 100 UNT/ML 485208 SCDC
- Insulin glulisine, human 100 UNT/ML [Apidra] 803192 SBDC

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

3 ML insulin glulisine, human 100 UNT/ML Pen Injector SCD · 847259
Insulin glulisine, human 100 UNT/ML SCDC · 485208
Insulin glulisine, human Pen Injector SCDF · 1651313
Insulin glulisine, human Injectable Product SCDG · 1157464

Brand-Name Concepts

Insulin glulisine, human 100 UNT/ML [Apidra] SBDC · 803192
Insulin glulisine, human Pen Injector [Apidra] SBDF · 1651315
Apidra Injectable Product SBDG · 1168563
Apidra BN · 607583

📦 FDA Products & Package NDCs

2 products · 4 package NDCs

4 package NDCs map to RxCUI 847261 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00088-2500-33	1 VIAL, GLASS in 1 CARTON (0088-2500-33) / 10 mL in 1 VIAL,...	Apidra	sanofi-aventis U.S. LLC	2009-02-24
00088-2500-34	1 VIAL, GLASS in 1 CARTON (0088-2500-34) / 10 mL in 1 VIAL,...	Apidra	sanofi-aventis U.S. LLC	2009-02-24
00088-2502-01	1 SYRINGE, PLASTIC in 1 CARTON (0088-2502-01) / 3 mL in 1 S...	Apidra SoloStar	sanofi-aventis U.S. LLC	2009-02-24
00088-2502-05	5 SYRINGE, PLASTIC in 1 CARTON (0088-2502-05) / 3 mL in 1 S...	Apidra SoloStar	sanofi-aventis U.S. LLC	2009-02-24

Observed labelers: sanofi-aventis U.S. LLC (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J1817	Insulin for insulin pump use	1	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.